The presence of intracellular elevated SphK1 expression correlates with clinical failure and poor survival in HNSCC patients and S1P-targeted therapy was put forward as a possible inclusion for resistant, hard-to-treat, HNSCC tumours [97]. The gene discussed is SPHK1; the disease is neoplasm.